# Intra-Cellular Probability Of Bankruptcy

ITCI | Stock | ## USD 52.53 1.04 1.94% |

Intra-Cellular | Probability Of Bankruptcy |

## Intra-Cellular Probability Of Bankruptcy Analysis

Intra-Cellular Ther's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years. 2021 | 2022 (projected) | |

Interest Expense | 33.1 K | 33.97 K |

Gross Profit | 75.77 M | 81.75 M |

Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Intra-Cellular Ther Probability Of Bankruptcy | 52% |

Most of Intra-Cellular Ther's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra-Cellular Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Intra-Cellular Ther probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Intra-Cellular Ther odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Intra-Cellular Ther financial health.

Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 5.1 B | Quarterly Revenue Growth YOY 1.77 | Return On Assets -0.28 | Return On Equity -0.5 |

The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

## Intra-Cellular Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Intra-Cellular Ther is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Intra-Cellular Ther's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intra-Cellular Ther's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intra-Cellular Ther's interrelated accounts and indicators.

**Click cells**to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Compare to competition |

Based on the latest financial disclosure, Intra-Cellular Ther has a Probability Of Bankruptcy of 52%. This is 20.12% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturersâ€”Specialty & Generic industry. The probability of bankruptcy for all United States stocks is 30.55% lower than that of the firm.

Chance Of Financial Distress

Over 52

Intra-Cellular Ther has

**more than 52 (%) percent**chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Intra-Cellular Ther stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info## Intra-Cellular Ther Main Bankruptcy Drivers

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Return on Average Assets | (0.26) | (0.39) | (0.5) | (0.38) | (0.48) | (0.52) | |

Total Liabilities | 17.05 M | 39.49 M | 56.18 M | 60.45 M | 72.03 M | 77.72 M | |

Current Liabilities | 14.21 M | 36.3 M | 36.22 M | 36.85 M | 53.36 M | 57.57 M | |

Total Assets | 471.49 M | 357.21 M | 251.19 M | 717.31 M | 489.92 M | 435.39 M | |

Current Assets | 469.22 M | 355.44 M | 230.32 M | 690.9 M | 467.28 M | 419.46 M | |

Net Cash Flow from Operations | (80.49 M) | (118.17 M) | (127.98 M) | (230.07 M) | (259.54 M) | (266.37 M) | |

Weighted Average Shares | 46.18 M | 54.71 M | 55.19 M | 70.36 M | 81.25 M | 66.43 M | |

Weighted Average Shares Diluted | 46.18 M | 54.71 M | 55.19 M | 70.36 M | 81.25 M | 66.54 M |

## Intra-Cellular Fundamentals

Return On Equity | (43.21) % | |||

Return On Asset | (24.72) % | |||

Profit Margin | (294.89) % | |||

Operating Margin | (296.47) % | |||

Current Valuation | 4.36 B | |||

Shares Outstanding | 81.46 M | |||

Shares Owned by Insiders | 2.43 % | |||

Shares Owned by Institutions | 91.82 % | |||

Number of Shares Shorted | 3.71 M | |||

Price to Earning | (6.56) X | |||

Price to Book | 8.96 X | |||

Price to Sales | 42.40 X | |||

Revenue | 102.92 M | |||

Gross Profit | (13.08 M) | |||

EBITDA | (304.55 M) | |||

Net Income | (303.5 M) | |||

Cash and Equivalents | 771.85 M | |||

Cash per Share | 8.18 X | |||

Total Debt | 24.39 M | |||

Debt to Equity | 0.03 % | |||

Current Ratio | 14.36 X | |||

Book Value Per Share | 5.98 X | |||

Cash Flow from Operations | (294.63 M) | |||

Short Ratio | 4.79 X | |||

Earnings Per Share | (3.20) X | |||

Price to Earnings To Growth | (0.08) X | |||

Number of Employees | 512 | |||

Beta | 1.24 | |||

Market Capitalization | 4.36 B | |||

Total Asset | 542.57 M | |||

Retained Earnings | (728.79 M) | |||

Working Capital | 401.13 M | |||

Current Asset | 541.82 M | |||

Current Liabilities | 140.69 M |

## About Intra-Cellular Ther Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra-Cellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra-Cellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra-Cellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.
## Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Analyst Recommendations Now

## Analyst RecommendationsAnalyst recommendations and target price estimates broken down by several categories |

All Next | Launch Module |

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Altman Z Score analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

## Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.

Pattern RecognitionUse different Pattern Recognition models to time the market across multiple global exchanges | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Watchlist OptimizationOptimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm | Go | |

Global CorrelationsFind global opportunities by holding instruments from different markets | Go | |

Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios | Go |

Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Market Capitalization 5.1 B | Quarterly Revenue Growth YOY 1.77 | Return On Assets -0.28 | Return On Equity -0.5 |

The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.